Integration of PARP-inhibitors in Ovarian Cancer Therapy

Overview

Journal Explor Target Antitumor Ther

Specialty Oncology

Date 2022 Sep 1

PMID 36046198

Authors

Antonella Pietragalla

Francesca Ciccarone

Camilla Nero

Giovanni Scambia

Domenica Lorusso

Gennaro Daniele

Affiliations

Soon will be listed here.

Abstract

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.

Citing Articles

Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands.

Teixeira R, Stefanelli A, Pilon A, Warmers R, Fontrodona X, Romero I J Med Chem. 2024; 67(8):6081-6098.

PMID: 38401050 PMC: 11056982. DOI: 10.1021/acs.jmedchem.3c01036.

References

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

Moore K, Secord A, Geller M, Miller D, Cloven N, Fleming G . Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. View

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-92. DOI: 10.1056/NEJMoa1105535. View

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R . Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25):2416-2428. DOI: 10.1056/NEJMoa1911361. View

Kaufman B, Shapira-Frommer R, Schmutzler R, Audeh M, Friedlander M, Balmana J . Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2014; 33(3):244-50. PMC: 6057749. DOI: 10.1200/JCO.2014.56.2728. View

Swisher E, Lin K, Oza A, Scott C, Giordano H, Sun J . Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 18(1):75-87. DOI: 10.1016/S1470-2045(16)30559-9. View

Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M . Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26):2495-2505. DOI: 10.1056/NEJMoa1810858. View

Konecny G, Kristeleit R . PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer. 2016; 115(10):1157-1173. PMC: 5104889. DOI: 10.1038/bjc.2016.311. View

10.

Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

11.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016; 17(11):1579-1589. DOI: 10.1016/S1470-2045(16)30376-X. View

12.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

13.

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

14.

Odell I, Wallace S, Pederson D . Rules of engagement for base excision repair in chromatin. J Cell Physiol. 2012; 228(2):258-66. PMC: 3468691. DOI: 10.1002/jcp.24134. View

15.

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

16.

Bajrami I, Frankum J, Konde A, Miller R, Rehman F, Brough R . Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2013; 74(1):287-97. PMC: 4886090. DOI: 10.1158/0008-5472.CAN-13-2541. View

17.

Oza A, Tinker A, Oaknin A, Shapira-Frommer R, McNeish I, Swisher E . Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017; 147(2):267-275. DOI: 10.1016/j.ygyno.2017.08.022. View

18.

Domchek S, Aghajanian C, Shapira-Frommer R, Schmutzler R, Audeh M, Friedlander M . Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016; 140(2):199-203. PMC: 4992984. DOI: 10.1016/j.ygyno.2015.12.020. View

19.

Kristeleit R, Shapiro G, Burris H, Oza A, LoRusso P, Patel M . A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors. Clin Cancer Res. 2017; 23(15):4095-4106. DOI: 10.1158/1078-0432.CCR-16-2796. View

20.

Berek J, Matulonis U, Peen U, Ghatage P, Mahner S, Redondo A . Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018; 29(8):1784-1792. DOI: 10.1093/annonc/mdy181. View